Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.59 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18665498 | 0.74 | F2 (0.55) | F2PRSS1PRSS2PRSS3SOS1 | |
| SCHEMBL7303158 | 0.74 | F2 (0.55) | F2PRSS1PRSS2PRSS3SOS1 | |
| SCHEMBL1124662 | 0.71 | F2 (0.52) | F2PRSS1PRSS2PRSS3SOS1 | |
| SCHEMBL31527705 | 0.70 | SOS1 (0.75) | SOS1CA1CA2PTGS2PTGS1 | |
| SCHEMBL283919 | 0.70 | SOS1 (0.75) | SOS1CA1CA2PTGS2PTGS1 | |
| SCHEMBL25376416 | 0.70 | F2 (0.50) | F2PRSS1PRSS2PRSS3SOS1 | |
| SCHEMBL580186 | 0.70 | F2 (0.50) | F2PRSS1PRSS2PRSS3SOS1 | |
| SCHEMBL7313933 | 0.70 | F2 (0.50) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL12662238 | 0.70 | F2 (0.50) | F2PRSS1PRSS2PRSS3SOS1 | |
| SCHEMBL26037516 | 0.70 | F2 (0.50) | F2PRSS1PRSS2PRSS3SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902372-B2 | Therapy for obesity; using a secondary amino compound | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080207701-A1 | OPIOID RECEPTOR ANTAGONISTS | CHAPPELL MARK DONALD | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207701-A1 | OPIOID RECEPTOR ANTAGONISTS | OPRD1, OPRM1, OPRK1 | F2 1891/4885PRSS1 656/4885PRSS2 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.